Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients

被引:83
作者
Fujiki, Youhei [1 ]
Kotani, Takuya [1 ]
Isoda, Kentaro [2 ]
Ishida, Takaaki [1 ]
Shoda, Takeshi [2 ]
Yoshida, Shuzo [1 ]
Takeuchi, Tohru [1 ]
Makino, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Yodogawa Christians Hosp, Dept Rheumatol, Internal Med, Osaka, Japan
关键词
Dermatomyositis; interstitial pneumonia; prognosis; LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; POLYMYOSITIS/DERMATOMYOSITIS; COMPLICATION; MYOSITIS; HRCT;
D O I
10.1080/14397595.2017.1318468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We retrospectively investigated clinical prognostic factors for interstitial pneumonia (IP) in anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM) patients. Methods: Subjects comprised 18 patients with anti-MDA5 Ab-positive DM-IP (9 survivors; 9 deaths). Results: Initial serum albumin levels, ferritin levels, and ground-glass opacity (GGO) scores in the right middle lobes were significantly higher in the death group than in the survivor group (p = .033, .013, and .005, respectively). Initial alveolar-arterial oxygen gradient (P[A-a]O-2) was also higher in the death group than in the survivor group (p = .064). Initial serum ferritin, P[A-a]O-2, and right middle lobe GGO score were found to significantly relate to death. Survival rates after 24 weeks were significantly lower among patients with an initial ferritin level of >= 450 ng/mL (25%), P[A-a]O-2 of >= 30 mmHg (31%), and a right middle lobe GGO score of >= 2 (11%) than each of the others (p = .006, .020, and .002, respectively). Conclusions: An initial serum ferritin level of >= 450 ng/mL, P[A-a]O-2 of >= 30 mmHg, and right middle lobe GGO score of >= 2 (GGO >= 5% of the lobe) were identified as poor prognostic factors for anti-MDA5 Ab-positive DM-IP patients.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
[21]   From machine learning to clinical practice: phenotypic clusters of anti-MDA5 antibody-positive dermatomyositis [J].
Koopman, Jacob J. E. ;
Buhler, Katherine A. ;
Choi, May Y. .
BRIEFINGS IN BIOINFORMATICS, 2024, 25 (04)
[22]   Anti-MDA5 dermatomyositis and progressive interstitial pneumonia [J].
Silveira, M. G. ;
Selva-O'Callaghan, A. ;
Ramos-Terrades, N. ;
Arredondo-Agudelo, K. V. ;
Labrador-Horrillo, M. ;
Bravo-Masgoret, C. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (01) :49-50
[23]   Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis [J].
Sakamoto, Noriho ;
Ishimoto, Hiroshi ;
Nakashima, Shota ;
Yura, Hirokazu ;
Miyamura, Takuto ;
Okuno, Daisuke ;
Hara, Atsuko ;
Kitazaki, Takeshi ;
Kakugawa, Tomoyuki ;
Ishimatsu, Yuji ;
Satoh, Minoru ;
Mukae, Hiroshi .
INTERNAL MEDICINE, 2019, 58 (06) :837-841
[24]   Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report [J].
Kodera, Hitoshi ;
Hirano, Reina ;
Akiyama, Masahiro ;
Matsumoto, Yoshifuji .
MODERN RHEUMATOLOGY CASE REPORTS, 2024, 8 (02) :291-295
[25]   Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis [J].
Wu, Wanlong ;
Guo, Li ;
Fu, Yakai ;
Wang, Kaiwen ;
Zhang, Danting ;
Xu, Wenwen ;
Chen, Zhiwei ;
Ye, Shuang .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2021, 60 (02) :293-304
[26]   Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients [J].
Qian, Jinjing ;
Li, Rui ;
Chen, Zhiwei ;
Cao, Zehui ;
Lu, Liangjing ;
Fu, Qiong .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[27]   Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis [J].
So, Ho ;
Wong, Victor Tak Lung ;
Lao, Virginia Weng Nga ;
Pang, Hin Ting ;
Yip, Ronald Man Lung .
CLINICAL RHEUMATOLOGY, 2018, 37 (07) :1983-1989
[28]   Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis [J].
Yoshinao Muro ;
Kazumitsu Sugiura ;
Masashi Akiyama .
Clinical Rheumatology, 2013, 32 :395-398
[29]   Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease [J].
Hata, Kenichiro ;
Kotani, Takuya ;
Matsuda, Shogo ;
Fujiki, Youhei ;
Suzuka, Takayasu ;
Kiboshi, Takao ;
Wada, Yumiko ;
Shiba, Hideyuki ;
Shoda, Takeshi ;
Kagitani, Maki ;
Takeuchi, Tohru .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (01)
[30]   Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases [J].
Kawasumi, Hidenaga ;
Katsumata, Yasuhiro ;
Nishino, Akira ;
Hirahara, Shinya ;
Kawaguchi, Yasushi ;
Kuwana, Masataka ;
Yamanaka, Hisashi .
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) :947-955